New India plant lifts Shasun's earnings; WTO may referee fight on Europe's API import rule;

> A $19 million investment in an API plant in Vizag, India, has helped Shasun Pharmaceuticals more than double its earnings in the last quarter. Story

> Swiss drugmaker Acino opened a new plant for transdermal therapeutic systems at the company's site in Miesbach, Germany. Release

> The FDA has OK'd a manufacturing change that will allow ViroPharma to scale up production of its injectable drug for hereditary angioedema, which causes swelling under the skin. Story

> India intends to set up pharmaceutical manufacturing in Sri Lanka as part of an effort to strengthen trade between the two countries. Story

> China and India may file a World Trade Organization complaint over the European Commission's pending rule that exporting countries must certify that APIs meet EC standards. Story

> Mylan ($MYL) says a subsidiary has started manufacturing 18 anti-retroviral products in India. Story

> And Finally... NPS Pharmaceuticals believes that its contract manufacturer will quickly resolve fill-and-finish issues that are keeping it from producing the drug to specifications so the company can submit its biologics license application for the bioengineered hormone Natpara by year's end. Story